Bridgewater Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Bridgewater Associates’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.4M	Sell	10,865 -2,492	-19%	-$1.1M	0.02%	468
2026 Q1	$5.96M	Sell	13,357 -14,131	-51%	-$6.59M	0.03%	379
2025 Q4	$12.5M	Sell	27,488 -10,836	-28%	-$4.67M	0.05%	299
2025 Q3	$15M	Buy	38,324 +3,934	+11%	+$1.64M	0.06%	253
2025 Q2	$15.3M	Buy	+34,390	New	+$15.8M	0.06%	212
2025 Q1	–	Sell	-710	Closed	-$286K	–	806
2024 Q4	$286K	Sell	710 -2,742	-79%	-$1.27M	﹤0.01%	634
2024 Q3	$1.61M	Sell	3,452 -29,777	-90%	-$14.3M	0.01%	542
2024 Q2	$15.6M	Sell	33,229 -101,466	-75%	-$44M	0.08%	187
2024 Q1	$56.3M	Buy	134,695 +2,341	+2%	+$990K	0.28%	69
2023 Q4	$53.9M	Sell	132,354 -25,995	-16%	-$9.6M	0.3%	65
2023 Q3	$55.1M	Sell	158,349 -17,964	-10%	-$6.28M	0.33%	59
2023 Q2	$62M	Sell	176,313 -27,963	-14%	-$9.42M	0.38%	54
2023 Q1	$64.4M	Buy	204,276 +103,457	+103%	+$31M	0.39%	55
2022 Q4	$29.1M	Sell	100,819 -63,172	-39%	-$19.3M	0.16%	119
2022 Q3	$47.5M	Sell	163,991 -53,161	-24%	-$15.3M	0.24%	83
2022 Q2	$61.2M	Buy	217,152 +187,000	+620%	+$50.1M	0.26%	80
2022 Q1	$7.87M	Buy	30,152 +17,735	+143%	+$4.21M	0.03%	352
2021 Q4	$2.73M	Sell	12,417 -2,700	-18%	-$525K	0.02%	420
2021 Q3	$2.74M	Sell	15,117 -8,139	-35%	-$1.59M	0.02%	387
2021 Q2	$4.69M	Buy	23,256 +1,567	+7%	+$328K	0.03%	341
2021 Q1	$4.66M	Buy	21,689 +18,059	+497%	+$3.97M	0.04%	228
2020 Q4	$858K	Buy	+3,630	New	+$833K	0.01%	405
2019 Q4	–	Sell	-32,260	Closed	-$5.46M	–	577
2019 Q3	$5.46M	Buy	+32,260	New	+$5.71M	0.05%	137
2019 Q2	–	Sell	-21,889	Closed	-$4.03M	–	369
2019 Q1	$4.03M	Buy	+21,889	New	+$4.04M	0.02%	155
2018 Q3	–	Sell	-15,509	Closed	-$2.64M	–	487
2018 Q2	$2.64M	Buy	+15,509	New	+$2.4M	0.03%	181
2017 Q3	–	Sell	-18,673	Closed	-$2.41M	–	397
2017 Q2	$2.41M	Buy	+18,673	New	+$2.25M	0.02%	156

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bridgewater Associates's VRTX Position: Q2 2026 in Review

Bridgewater Associates reduced its Vertex Pharmaceuticals (VRTX) stake by 19% in Q2 2026, selling an estimated $1.1M and leaving 10,865 shares worth $5.4M. The position accounts for 0.02% of the portfolio, ranked #468.

Bridgewater Associates first reported a position in VRTX in Q2 2017 and has held it in 26 quarters since. The position peaked at $64.4M in Q1 2023. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Bridgewater Associates held 10,865 shares of Vertex Pharmaceuticals worth $5.4M as of Q2 2026.
Bridgewater Associates sold 2,492 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.1M.
Vertex Pharmaceuticals made up 0.02% of Bridgewater Associates's portfolio in Q2 2026, its #468 holding.
Bridgewater Associates first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 26 quarters since.
Bridgewater Associates's Vertex Pharmaceuticals position peaked at $64.4M in Q1 2023.
1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.